Helixate NexGen is a powder and solvent that are mixed together to make up a solution for injection. Helixate NexGen contains the active substance human coagulation factor VIII (octocog alfa).
|Table of Contents|
|What is it used for?|
|How is it used?|
|How does it work?|
|How has it been studied?|
|What benefits has it shown during the studies?|
|What is the risk associated?|
|Why has it been approved?|
Helixate NexGen is used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder). Helixate NexGen is intended for either short-term or long-term use.
The medicine can only be obtained with a prescription.
Helixate NexGen should be started by a doctor who has experience in the treatment of haemophilia.
Helixate NexGen is given by injection into a vein lasting several minutes. The dose and frequency of injection depend on whether Helixate NexGen is used to treat or prevent bleeding, or to reduce bleeding during surgery. The dose is adjusted depending on the severity and location of the bleeding, or the type of surgery. Helixate NexGen can also be given continuously for up to seven days as an infusion (drip into a vein) in patients undergoing major surgery.
Full details on how to calculate the doses are included in the summary of product characteristics (also part of the EPAR).
The active substance in Helixate NexGen, human coagulation factor VIII, is a substance that helps the blood to clot. Patients with haemophilia A lack factor VIII, which causes blood clotting problems such as bleeding in the joints, muscles and internal organs. Helixate NexGen is used to correct the factor VIII deficiency by replacing the missing factor VIII, giving temporary control of the bleeding disorder.
The human coagulation factor VIII in Helixate NexGen is not extracted from human blood but is produced by a method known as ?recombinant DNA technology?: it is made by a cell that has received a gene (DNA), which makes it able to produce human coagulation factor VIII.
Helixate NexGen is similar to another medicine that was previously authorised in the European Union (EU) called Helixate, but it is prepared differently so that there are no human-derived proteins in the medicine. Because of this, Helixate NexGen has been compared with Helixate to show that the two medicines are equivalent.
Helixate NexGen given as an injection into a vein has been studied in 66 patients who had previously been treated with recombinant human coagulation factor VIII and 61 children who had not. The main measure of effectiveness in the studies was the number of treatments required to stop each new bleed.
Helixate NexGen as a continuous infusion has also been studied in 15 patients with haemophilia A undergoing major surgery. The main measure of effectiveness was the doctor?s assessment of how well bleeding was stopped.
In the previously treated patients, overall, 95% of bleeds responded to one or two injections of Helixate NexGen into a vein. In the previously untreated patients, about 90% of bleeding episodes responded to treatment with one or two injections into a vein.
When given as a continuous infusion, stopping bleeding was assessed as ?excellent? in all 15 patients.
Haemophilia A patients may develop antibodies (inhibitors) to factor VIII. If this happens, Helixate NexGen will not work effectively, which may result in a loss of bleeding control. The most common side effects with Helixate NexGen (seen in between 1 and 10 patients in 100) are reactions at the infusion site and skin-associated hypersensitivity (allergic) reactions (itching, hives and rash). For the full list of all side effects reported with Helixate NexGen, see the package leaflet.
Helixate NexGen must not be used in people who are known to be hypersensitive (allergic) to human coagulation factor VIII or to any of the other ingredients. It must also not be used in people who are known to have allergic reactions to mouse or hamster protein.